The Technical Analyst
Select Language :
MacroGenics Inc [MGNX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

MacroGenics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

MacroGenics Inc is listed at the  Exchange

-1.60% $14.72

America/New_York / 28 mar 2024 @ 16:00


MacroGenics Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 913.07 mill
EPS: 0.810
P/E: 18.17
Earnings Date: Mar 13, 2024
SharesOutstanding: 62.03 mill
Avg Daily Volume: 1.404 mill
RATING 2024-03-28
B-
Sell
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Buy
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 18.17 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
3.09x
Company: PE 18.17 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$-0.0136
(-100.09%) $-14.73
Date: 2024-03-28
Expected Trading Range (DAY)

$ 13.24 - 16.21

( +/- 10.09%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-06 Peters Jeffrey Stuart Sell 8 750 Employee stock option (right to buy)
2024-03-06 Peters Jeffrey Stuart Buy 8 750 Common Stock
2024-03-06 Peters Jeffrey Stuart Buy 10 875 Common Stock
2024-03-06 Peters Jeffrey Stuart Sell 19 625 Common Stock
2024-03-06 Peters Jeffrey Stuart Sell 10 875 Employee stock option (right to buy)
INSIDER POWER
48.22
Last 100 transactions
Buy: 2 029 319 | Sell: 658 073

Forecast: 16:00 - $14.72

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $14.72
Forecast 2: 16:00 - $14.72
Forecast 3: 16:00 - $14.72
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $14.72 (-1.60% )
Volume 0.771 mill
Avg. Vol. 1.404 mill
% of Avg. Vol 54.92 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for MacroGenics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for MacroGenics Inc

RSI

Intraday RSI14 chart for MacroGenics Inc

Last 10 Buy & Sell Signals For MGNX

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:34sell$18.50N/AActive
Profile picture for
            MacroGenics Inc

MGNX

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Last 10 Buy Signals

Date Signal @
DPXUSDMar 29 - 02:4542.45
WBTUSDMar 29 - 02:428.37
TUSDUSDMar 29 - 02:41$0.994
BGBUSDMar 29 - 02:300.996
PEPECOINUSDMar 29 - 02:245.83
VRXUSDMar 29 - 02:1960.44
^N300Mar 29 - 02:00594.52
CBKUSDMar 29 - 02:151.087
ORCAUSDMar 29 - 02:153.83
TRXUSDMar 29 - 02:10$0.120

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.